The company's lead candidate, pegozafermin, is currently in Phase III clinical trials for the treatment of Metabolic Associated Steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG).
89bio's main value driver is Pegozafermin. It has two Phase 3 trials: one for MASH and the other for SHTG. Management mentioned we should get its SHTG topline data by 2H2025. This could be a ...
The firm's confidence in the biopharmaceutical company's prospects is tied to the progress of its Phase 3 ENTRUST study of pegozafermin, a treatment for severe hypertriglyceridemia (SHTG).
Proceeds from the offering will support ongoing clinical trials, particularly for their lead candidate, pegozafermin, as well as manufacturing costs and general corporate expenses. The offering is ...
“We remain confident in pegozafermin's potential as a potent anti-fibrotic agent with broad cardio-metabolic benefits. With a strengthened leadership team, commercial-scale manufacturing ...
89bio intends to use the net proceeds from this proposed offering to fund ongoing clinical activities and development of pegozafermin, manufacturing related costs and other general corporate ...
The company's lead candidate, pegozafermin, is currently in Phase III clinical trials for the treatment of Metabolic Associated Steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). According ...